SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy
Liang, B.; Zhang, E. H.; Ye, Z.; Storts, H.; Jin, W.; Zheng, X.; Zaleski, O.; Xing, X.; Wang, J. J.
Show abstract
The cGAS/STING cytosolic DNA sensing pathway plays a central role in anti-tumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regulator of STING expression in colon cancer cells. We showed that knockout of SIX4 decreased STING expression at the mRNA and protein levels while ectopic expression of SIX4 increased STING expression. Depletion of SIX4 led to attenuated STING activation and downstream signaling. Re-expression of SIX4 or ectopic expression of STING in SIX4 knockout cells reversed the effect. Ectopic expression of SIX4 enhanced DMXAA and cGAMP-induced STING activation and downstream signaling. Importantly, decrease of SIX4 expression substantially decreased tumor infiltration of CD8+ T-cells and reduced the efficacy of PD-1 antibodies to diminish tumor growth in immune competent mice in vivo. Finally, analysis of TCGA colon cancer dataset indicated that tumors with high SIX4 expression were significantly enriched in the Inflammatory Response pathway. SIX4 expression also correlated with expression of multiple IFN-stimulated genes, inflammatory cytokines and CD8A. Taken together, our results implicate that SIX4 is a principal regulator of STING expression in colon cancer cells, providing an additional mechanism and genetic marker to predict effective immune checkpoint blockade therapy responses.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 93%
- TROP2 represents a negative prognostic factor in colorectal adenocarcinoma and its expression is associated with features of epithelial-mesenchymal transition and invasiveness 93%
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 93%
Similar papers in this journal
- Inhibition of O-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway 94%
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 94%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 94%
Similar papers in this journal
- The most common RNF43 mutant G659Vfs41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis 93%
- PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma 93%
- Interferon-γ Increases Sensitivity to Chemotherapy and Provides Immunotherapy Targets in Models of Metastatic Castration-Resistant Prostate Cancer 93%
Similar papers in this journal
- Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice 94%
- CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming 94%
- Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity 93%
Similar papers in this journal
- Interferon-Gamma Signaling Promotes Melanoma Progression and Metastasis 93%
- Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition 93%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.